Stop-and-go cancer therapy disappointsIntermittently administering therapy to people with cancer leads to faster tumour growth and no improvement in long-term survival, researchers have reported at a conference, contradicting expectations that came in part from a 2013 study in mice. In a five-year clinical trial, 250 people with advanced melanoma took a drug that blocks a mutant protein involved in tumour growth. For some participants, clinicians suspended the therapy after 8 weeks, and then resumed it periodically. In this group, tumours began growing again after 5.5 months on average, compared with 9 months for those who continuously received the drug. “The results are the opposite of what we expected and all the preclinical data would have predicted,” says cancer researcher Antoni Ribas. Science | 6 min read |
No hay comentarios:
Publicar un comentario